BJH - 2021, issue SPECIAL, january 2021
Prof J. Apperley
The therapeutic landscape of chronic myeloid leukaemia (CML) has changed dramatically over the past decades and the majority of patients with Philadelphia chromosome-positive (Ph+) CML in chronic phase (CP) now have a near-normal life expectancy.1 Based on two recent published guidelines (European LeukemiaNet (ELN) guideline1 and the British Society for Haematology guideline2) and the presentation by Prof. Jane Apperley during the 2021 BHS GAM, this article will give an overview of the latest developments in the therapeutic CML landscape and address a range of the persistent unmet needs in the diagnosis and treatment of CP-CML.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
